The 68th Annual General Assembly Scientific Meeting of the Japan College of Rheumatology
International Concurrent Workshop

April 18 (Thu)

Session ID		Name	Affiliation	Title
ICW1 Biomarkers 1 9:40-10:40 Room 8	Chair	Naoki Iwamoto	Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan	
	Chair	Christopher Ritchlin	Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA	
	ICW1-1	Madhu Baghel	Henry Ford Health + Michigan State University Health Sciences, Detroit, USA	MicroRNAs as circulating biomarkers for distinguishing early rheumatoid arthritis
	ICW1-2	Takakura Yuto	Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University Ohashi Medical Center, Tokyo, Japan	Soluble tumor necrosis factor receptor 1 as a predictive biomarker of relapse after discontinuation of biological agents and response to re-treatment in rheumatoid arthritis.
	ICW1-3	Keisuke Izumi	Department of Rheumatology, NHO Tokyo Medical Center	Smartphone-acquired patient reported outcomes and smartwatch sensing data in rheumatoid arthritis: a multicenter single-arm prospective study for digital biomarker
	ICW1-4	Withdrawn		
	ICW1-5	Suwa Yuichi	Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan	Single cell RNA-sequencing analysis reveals quantitative and qualitative alterations of dendritic cells in rheumatoid arthritis.
ICW 2 Vasculitis 1 10:50-11:50 Room 8	Chair	Masayuki Nishide	Department of Respiratory Medicine and Clinical Immunology, Osaka University	
	Chair	Meng-Ko Tsai	Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan	
	ICW2-1	Mayu Shiomi	Department of Neurology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan	Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: the multicenter REVEAL cohort study
	ICW2-2	Tsuneyasu Yoshida	Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan	Real-World Analysis of Avacopan Usage in Patients with Microscopic Polyangiitis: The Multicenter REVEAL Cohort Study
	ICW2-3	Shogo Matsuda	Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University	Poor prognostic factors for predicting relapse of interstitial lung disease in microscopic polyangiitis: multicenter study in Japan -the REVEAL cohort study-
	ICW2-4	Kotaro Matsumoto	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine	Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule
	ICW2-5	Mayu Shiomi	Department of Neurology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan	Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study
	ICW2-6	Masayuki Nishide	Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine	Different immunological phenotypes of microscopic polyangiitis identified by single-cell multi-omics analysis
ICW3 Clinical study in RA 1 9:40-10:40 Room 9	Chair	Hiroki Mitoma	Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital	
	ICW3-1	Hajime Inokuchi	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan	Factors associated with progression of chronic kidney disease in rheumatoid arthritis patients who treated with methotrexate monotherapy.
	ICW3-2	Yasumori Sobue	Department of Orthopedic Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan	Frailty is associated with a reduced frequency of vocalization in rheumatoid arthritis patients.
	ICW3-3	York Kiat Tan	Department of Rheumatology and Immunology, Singapore General Hospital, Singapore	Thermographic detection of subclinical joint inflammation at the elbow of patients with rheumatoid arthritis: a comparison with ultrasonography
	ICW3-4	Hiroki Kohno	Division of Respiratory Medicine and Rheumatology, Tottori University Hospital	Relationship between types of passive smoking and onset of rheumatoid arthritis
	ICW3-5	Masato Tarumi	Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan	Fish consumption influences treatment response in patients with rheumatoid arthritis on molecular targeted therapy.
ICW4 Pathophysiology of RA 1 10:50-11:50 Room 9	Chair	Hirofumi Shoda	Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo	
	Chair	Josef S. Smolen	Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria	
	ICW4-1	Withdrawn		
	ICW4-2	Jiaqing Liu	Department of Immunology, School of Basic Medicine, Dalian Medical University, Dalian, China	MiDs enhanced mitochondrial fission contributes to proinflammatory characteristics of RASF through activation of mitophagy
	ICW4-3	Jinghui Yu	Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan	Interleukin-26 facilitates hyperplasia of synovium and cartilage destruction in a collagen antibody-induced arthritis model.
	ICW4-4	Alfonso Del Peral Fanjul	Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine	Myeloid-derived suppressor cells from the inflamed joints of arthritic SKG mice differentiate into osteoclasts and promote bone resorption.
	ICW4-5	Yoichi Nakayama	Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan	Cytosporone B, a Selective Agonist of Nr4a1, Alleviates Experimental Arthritis in SKG mice
	ICW4-6	Sho Sendo	Department of Clinical Laboratory/ Division of Rheumatology and Clinical Immunology, Kobe university hospital	Negative Regulation of Neddylation Reduces RA FLS Inflammatory Responses and Arthritis in Mouse Model
ICW5 bDMARDs for RA 9:40-10:40 Room 10	Chair	Kosuke Ebina	Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine	
	Chair	Daniel Aletaha	Medical University of Vienna, Vienna, Austria	
	ICW5-1	Bogdan I. Gavrila	University of Medicine and Pharmacy "Carol Davila", "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania	Immunological remission, prognosis and smoking impact in rheumatoid arthritis among patients treated with TNF inhibitors
	ICW5-2	Claudia S. Ciofu	University of Medicine and Pharmacy "Carol Davila", "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania	Immunological remission among new proposed diagnostic biomarkers and their predictive role to TNFi treatment response in rheumatoid arthritis
	ICW5-3	Kichul Shin	College of Medicine, Seoul National University	Effectiveness of the first etanercept biosimilar for Korean patients with rheumatoid arthritis in real-world practice
	ICW5-4	Yurie Satoh Kanda	The First department of internal medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Efficacy of Tocilizumab (TCZ) for skin sclerosis in Systemic sclerosis (SSc) complicated with rheumatoid arthritis (RA)
	ICW5-5	Ryu Watanabe	Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan	Efficacy of ozoralizumab based on baseline rheumatoid factor titers in patients with rheumatoid arthritis and an inadequate response to methotrexate: Post hoc analysis of a Phase II/III study (OHZORA trial)
	ICW5-6	Akira Onishi	Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine	Comparative effectiveness of subcutaneous sarilumab, subcutaneous tocilizumab and intravenous tocilizumab in patients with rheumatoid arthritis: the ANSWER cohort study

April 18 (Thu)

Session ID		Name	Affiliation	Title
ICW6 Clinical study in RA 2 10:50-11:50 Room 10	Chair	Kosaku Murakami	Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University	
	Chair	Annamaria Iagnocco	University of Turin, Italy	
	ICW6-1	Mari Yamamoto	Department of Rheumatology and Nephrology, Chubu Rosai Hospital, Aichi, Japan	Improvement in Disease Activity Assessment Frequency in Rheumatoid Arthritis Patients through the Introduction of the "MiRAi" System: An Observational Study on Enhancing Quality in Routine Clinical Practice
	ICW6-2	Naomi Hanaka	Orthopedics, Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata	Circulated cooperation of the hospital and polyclinic for rheumatoid arthritis treatment in Yamagata area-Current Status and Challenges of YARANNA NET over the Past 10 Years-
	ICW6-3	Tomoaki Higuchi	Department of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University Hospital	Association between continuous achievement of 2022 American College of Rheumatology /EULAR revised remission criteria and functional remission in patients with rheumatoid arthritis-results from the IORRA cohort
	ICW6-4	Naohiro Sugitani	Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan	Investigation of major cardiovascular events (MACE) in recent Japanese patients with rheumatoid arthritis: results from the IORRA cohort
	ICW6-5	Nozomi Nishimura	Department of Rheumatology and clinical immunology, Graduate school of medicine, Kyoto university	Comparative risks of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis: the ANSWER cohort study
	ICW6-6	Ryuichiro Kanda	First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Efficacy and safety of bDMARDs in interstitial lung disease of rheumatoid arthritis (RA-ILD): from the FIRST registry
ICW7 Biomarkers 2 14:20-15:20 Room 8	Chair	Satoshi Kubo	Department of Molecular Targeted Therapies (DMTT), School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	
	Chair	Gerd R. Burmester	Department of Rheumatology and Clinical Immunology, Charité - Università tsmedizin, Berlin, Germany	
	ICW7-1	Ashkan F. Ara	University of California, Los Angeles (UCLA)	Serum Anti-NR2 Exhibits Higher Specificity than Sensitivity in the Diagnosis of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
	ICW7-2	Ching Ju Chen	Chi Mei Medical Center, Clinical Pathology, Tainan, Taiwan	Associations of Antinuclear antibody with mitochondrial antibody and smooth muscle antibody in autoimmune liver diseases
	ICW7-3	Yuki Kudo	Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan	Serum C-type lectin domain family 7 member A as a potential novel biomarker for disease activity in patients with systemic lupus erythematosus
	ICW7-4	Yusuke Yoshida	Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital	Serum calprotectin as a potential marker for macrophage activation syndrome in patients with systemic lupus erythematosus
	ICW7-5	Tomoya Nakajima	Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan	Serum C-reactive protein levels can predict organ damage within 2 years in patients with systemic lupus erythematosus who meet Lupus Low Disease Activity State
ICW8 Biomarkers 3 15:30-16:30 Room 8	Chair	Satoshi Yamasaki	Department of Rheumatology, Medical Corporation JR Hiroshima Hospital	
	Chair	Bernhard Hellmich	Medius Kliniken, University of Tübingen, Kirchheim-Teck, Germany	
	ICW8-1	Ranjan Gupta	All India Institute of Medical Sciences, New Delhi	Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
	ICW8-2	Yusuke Miyazaki	The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Clinical features and peripheral blood immunophenotype of patients with SLE in maintenance phase who were able to discontinue glucocorticoids after intervention with belimumab
	ICW8-3	Yasuyuki Todoroki	Department of Molecular Targeted Therapies (DMTT), School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Significance of T-bet positive CD11c+ B cells in patients with systemic lupus erythematosus (SLE)
	ICW8-4	Satoshi Kubo	Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Stratification of treatment-naïve systemic lupus erythematosus into four distinct immune phenotype groups exhibiting variable relapse rates
	ICW8-5	Yurie Satoh Kanda	The First department of internal medicine, University of Occupatinal and Environmental Health, Japan, Kitakyushu, Japan	Clinical significance of follicular helper T (Tfh) cell subsets in systemic lupus erythematosus (SLE)
ICW9 Clinical study in RA 3 14:20-15:20 Room 9	Chair	Yoshinori Matsumoto	Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan	
	Chair	Jose Paulo Lorenzo	APLAR President-Elect / Makati Medical Center and the University of the Philippines, Philippine General Hospital （UP-PGH）, Philippines	
	ICW9-1	Jun Nagai	Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan	The benefit of preoperative simulated surgery using a 3D model in reverse shoulder arthroplasty in cases of glenoid defect and deformity.
	ICW9-2	Farah F. Mohammed Mubarak	Consultant in Rheumatology and Rehabilitation Medicine, District General Hospital Nawalapitiya, Sri Lanka	An Audit on Monitoring of Non-biological Disease-Modifying Anti-Rheumatic Drugs Among Patients with Inflammatory Rheumatological Diseases, Followed up at Rheumatology Clinic of District General Hospital Nawalapitiya, Sri Lanka
	ICW9-3	Yasushi Naganuma	Department of Orthopaedic Sugery, Nihonaki General Hospital, Yamagata, Japan	Mid-term clinical outcomes of non-constrained total elbow arthroplasty in rheumatoid arthritis
	ICW9-4	Naoki Kondo	Orthopedic Surgery, Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan	Long-term clinical outcome of the metatarsophalangeal joint arthroplasty (Swanson silicone hinge-toe implant) for rheumatoid foot deformities.
	ICW9-5	Kiara H. Quinncilla	Jakarta Islamic Hospital, Indonesia	Short-term and long-term outcomes of rheumatoid arthritis patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
	ICW9-6	Kazunori Furuhashi	Rheumatology, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan	Sufficient methotrexate-polyglutamate concentration predict future improvement of joint inflammation detected by ultrasonography in patients with rheumatoid arthritis
ICW10 Antiphospholipid syndrome and Sjögren's syndrome 15:30-16:30 Room 9	Chair	Keisuke Izumi	Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine	
	Chair	Paul Bird	St George Clinical School, University of New South Wales	
	ICW10-1	Qingyi Lu	Department of Rheumatology and Immunology,Peking University People's Hospital,Beijing,China	Clinical significance of ceramide antibody in antiphospholipid syndrome
	ICW10-2	Hiroyuki Fukui	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan	Mass cytometrical approach to reveal immune cell profiles associated with Sjögren's syndrome
	ICW10-3	Mitsutaka Yasuda	Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan	Significance of clinical domains (venous or arterial thrombosis) in the 2023 ACR/EULAR antiphospholipid syndrome classification criteria
	ICW10-4	Yu Shi	Chinese Academy of Medical Sciences, Peking Union Medical College Hospital	Platelets are highly activated and might participate in immune abnormality of APS
	ICW10-5	Zhou Zhou	Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei,China	TLR2 promotes cytotoxicity and inflammatory response of CD8+T cells by activating mitochondrial autophagy in primary Sjogren's syndrome
	ICW10-6	Haruka Moriya	Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan	Monocyte/HDL-Cholesterol Ratio as a Potential Indicator of Recurrent Thrombosis inPatients with Antiphospholipid Syndrome

April 18 (Thu)

Session ID		Name	Affiliation	Title
ICW11 Lupus nephritis 14:20-15:20 Room 10	Chair	Shigeru Iwata	Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan	
	Chair	Roy M. Fleischmann	University of Texas Southwestern Medical Center, USA	
	ICW11-1	Takehiro Nakai	Immuno-Rheumatology Center, St. Luke's International Hospital	Change in the SLE mortality rate and prevalence of lupus nephritis overtime: Single center retrospective study in Japan
	ICW11-2	Xu Zheng	Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China,Hefei, Anhui, China	apopDNA promotes lupus nephritis in mice by mediating macrophage pyroptosis through AIM2/Caspase-1/GSDMD pathway
	ICW11-3	Withdrawn		
	ICW11-4	Masanobu Ueno	The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Effectiveness and safety of rituximab in patients with lupus nephritis -LOOPS registry-
	ICW11-5	Hidenori Sakai	The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Efficacy, safety and optimal intervention of belimumab in patients with active lupus nephritis in the real-life clinical setting from LOOPS registry
ICW12 Biologics for SLE 15:30-16:30 Room 10	Chair	Haruka Tsuchiya	Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo	
	Chair	Andrea Fava	Division of Rheumatology, Johns Hopkins University, Baltimore, USA	
	ICW12-1	Masataka Umeda	Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical	Successful Treatment of Systemic Lupus Erythematosus with Residual Disease Activity by Switching from Belimumab to Anifrolumab
	ICW12-2	Yasuhiro Hasegawa	Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan	Prediction of the low disease activity and remission after 1-year of treatment with Belimumab in Patients with Systemic Lupus Erythematosus
	ICW12-3	Zhu Chen	Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China	Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a retrospective, multicenter real-world study
	ICW12-4	Shunsuke Kyoda	Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine	Potentially different effects of biologics for patients with systemic lupus erythematosus (SLE) on short-term changes of patient-reported outcome
	ICW12-5	Satsuki Matsunaga	The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan	Safety and Efficacy of Anifrolumab in patients with Systemic Lupus Erythematosus (SLE) with minor flares after achieving LLDAS from LOOPS registry